The statistical treatment for noninferiority averts such possible ambiguity by instead assigning P values <0.05, where there is genuine, adequately powered equivalence or noninferiority. The noninferiority testing reported here applied an alpha of 5%, a 90% confidence interval, and a noninferiority margin of 5%. The statistical analysis of noninferiority combined the screening test outcomes from both the male hemizygous selleck compound and female heterozygous

models. We reasoned that the percent of normal G6PD activity in the RBC suspension as a whole, regardless of the means of its compromise, represented the key determinant of diagnostic performance. Noninferiority of CSG to FST was assessed at discrete levels of residual G6PD activity, a key advantage of the CuCl model over naturally G6PD-deficient RBCs for this purpose. We examined the diagnostic performance of the FST and CSG relative to quantitative G6PD activity using standard estimates of sensitivity, specificity, positive predictive value, and negative selleck kinase inhibitor predictive value for each. This approach required establishing a firm threshold of G6PD activity for positivity for G6PD deficiency. We chose ≤40% of normal values as the

threshold. We reasoned that hemizygotes having higher levels than this threshold could safely receive primaquine therapy. However, it is acknowledged that such a threshold is not grounded in sufficient clinical evidence, and it may not apply to heterozygous females for the complex reasons explained. Nonetheless, these diagnostic performance characteristics tuclazepam provide a useful, even if strictly limited, metric of diagnostic performance in the context of screening for primaquine therapy. The 5 treatments with CuCl (0.2, 0.4, 0.6, 0.8, and 1.0 mM) modeling hemizygous states resulted in levels of G6PD inhibition ranging from slight with 0.2 mM

CuCl to as much as 95% with 1.0 mM CuCl. These values represented a continuum between 138% (9.6 U/gHb) and 5% (0.4 U/gHb) of the mean value from samples not exposed to CuCl (6.9 U/gHb) in that series. A similar continuum of G6PD activity occurred among the variable proportions of CuCl-treated (1.0 mM) RBC modeling heterozygous states. The mean-untreated G6PD activity was 7.8 U/gHb in that series and ranged between 10.8 and 0.8 U/gHb (138%–10% of normal, respectively). The analysis of noninferiority of CSG to FST treated G6PD activity as a continuous variable rather than according to groups of CuCl treatment. Table I lists the results of this analysis. Qualitative test outcomes were pooled into groups according to percent of normal G6PD activity in increments of 10 percentiles and each statistically analyzed for noninferiority. At all levels of G6PD activity except the lowest and highest increments (which were inconclusive because of inadequate sample size), the diagnostic performance of the CSG was not inferior to the FST, with P values ranging from 0.006 to <0.001. Fig 3 illustrates all these test outcomes grouped in increments of 0.25 U/gHb.